Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain molecular remiss...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of hematology and oncology Vol. 16; no. 1; p. 43
Main Authors:	Pavlovsky, Carolina, Vasconcelos Cordoba, Bianca, Sanchez, María Belén, Moiraghi, Beatriz, Varela, Ana, Custidiano, Rosario, Fernandez, Isolda, Freitas, Maria Josefina, Ventriglia, Maria Verónica, Bendek, Georgina, Mariano, Romina, Mela Osorio, María José, Pavlovsky, Miguel Angel, de Labanca, Ana García, Foncuberta, Cecilia, Giere, Isabel, Vera, Masiel, Juni, Mariana, Mordoh, Jose, Sanchez Avalos, Julio Cesar, Cueto, Gerardo, Miranda, Silvia, Levy, Estrella Mariel, Bianchini, Michele
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 29-04-2023 BioMed Central BMC
Subjects:	Accuracy Biomarkers Chronic myeloid leukemia Cloning Correspondence Cytokines Data mining Hematology Humans Interleukin 6 Kinases Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Machine learning Monocyte chemoattractant protein 1 Myeloid leukemia Oncology Plasma Plasma levels Predictive factors Protein Kinase Inhibitors Remission Remission (Medicine) Remission Induction Stem cells Treatment free remission Treatment Outcome Latin America Treatment free remission Chronic myeloid leukemia Cytokines Predictive factors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain molecular remission, and the prior time in deep molecular response (DMR) was associated with successful TFR. Luminex technology was used to characterize cytokines in plasma samples. Using machine learning algorithms, MCP-1 and IL-6 were identified as novel biomarkers and MCP-1 /IL-6 patients showed eightfold higher risk of relapse. These findings support the feasibility of TFR for patients in DMR and MCP-1/IL-6 plasma levels are strong predictive biomarkers.
Bibliography:	SourceType-Other Sources-1 ObjectType-Article-2 content type line 63 ObjectType-Correspondence-1
ISSN:	1756-8722 1756-8722
DOI:	10.1186/s13045-023-01440-6